Answer ALS Partnership

The Les Turner ALS Foundation is very pleased to announce the Les Turner ALS Research and Patient Center at Northwestern Medicine as the newest member of the single largest coordinated and collaborative effort to end ALS in the history of …

7th Annual Les Turner Symposium on ALS and NeuroRepair

The 7th Annual Les Turner Symposium on ALS and NeuroRepair will held on Monday, November 6 at Prentice Women’s Hospital. Celebrating research, patient care and education–attendees will get the opportunity to learn the latest on ALS drug development. Christopher Henderson, …

Radicava is Now Available for Treatment in U.S

Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA ™ (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is now available for treatment in the United States. RADICAVA, …

Collaboration in Research

A recent publication in Neurology Today highlights the research of Dr. Sabrina Paganoni who is testing a drug to slow the progression of ALS. This study is being done in collaboration with Les Turner ALS Research and Patient Center at Northwestern Medicine …

Investing in our Future: Funding ALS Research

Each year, the Les Turner ALS Foundation provides a grant to the Les Turner ALS Research and Patient Center at Northwestern Medicine. This grant provides support to the Lois Insolia ALS Clinic as well as researchers looking for answers on …

Radicava FAQs

Les Turner ALS Research and Patient Center at Northwestern Medicine On May 5, the FDA approved a new drug to treat ALS. Radicava™ (also known as Edaravone) is the first approved ALS-specific drug since Riluzole, which was approved 22 years …